enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Eli Lilly Alzheimer's drug approved by US FDA - AOL

   www.aol.com/news/us-fda-approves-lillys...

   The approval for donanemab, to be sold under the brand name Kisunla, followed the recommendations of the agency's outside experts, who unanimously backed its use in patients with early Alzheimer's ...

3. US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10

   www.aol.com/news/us-fda-panel-discuss-eli...

   Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of its advisers to discuss the drug, further delaying its ...

4. Eli Lilly's Potential Alzheimer’s Drug Clears a Big Hurdle

   www.aol.com/eli-lillys-potential-alzheimer-drug...

   A panel of brain and Alzheimer’s experts convened by the U.S. Food and Drug Administration (FDA) voted unanimously on June 10 that a new Alzheimer’s drug developed by Eli Lilly, called ...

5. Donanemab - Wikipedia

   en.wikipedia.org/wiki/Donanemab

   Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.

6. Donanemab – what we know about the latest Alzheimer’s drug

   www.aol.com/donanemab-know-latest-alzheimer-drug...

   The US Food and Drug Administration (FDA) approved Kisunla for the treatment of Alzheimer’s disease in July. Breaking News: The FDA has granted approval of Kisunla (donanemab) for the treatment ...

7. US FDA delays Lilly Alzheimer's drug decision, calls for ...

   www.aol.com/news/us-fda-delays-lilly-alzheimers...

   The FDA's decision came as a surprise to company officials and many Alzheimer's experts, who had expected a full approval for Lilly's drug donanemab this month based on clinical trial data last ...

8. FDA approves a second Alzheimer’s drug that can ... - AOL

   www.aol.com/fda-approves-second-alzheimer-drug...

   The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and ...

9. Romosozumab - Wikipedia

   en.wikipedia.org/wiki/Romosozumab

   Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [ 7 ] [ 8 ] It has been found to decrease the risk of fractures of the spine .